Ascendis Pharma (ASND)

• Market cap: $12.1B
• 1 day: 1.19%
• 5 days: 0.68%
• 1 month: 2.84%
• 3 months: 15.44%
• 6 months: 18.21%
• Year to date: 44.63%
• 1 year: 36.16%
• 5 years: 36.98%
• 10 years: 899.95%
• Sector: Healthcare
• Industry: Biotechnology

About: Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.

Employees: 1,017

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

210% more call options, than puts

Call options by funds: $39.2M | Put options by funds: $12.6M

14% more funds holding in top 10

Funds holding in top 10: 14 [Q1] → 16 (+2) [Q2]

10% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 40

7% more capital invested

Capital invested by funds: $10.1B [Q1] → $10.9B (+$708M) [Q2]

1% more funds holding

Funds holding: 241 [Q1] → 244 (+3) [Q2]

2% less repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 85

4.51% less ownership

Funds ownership: 107.4% [Q1] → 102.88% (-4.51%) [Q2]

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $203
• Avg. target: $254
• High target: $307

10 analyst ratings

• positive: 10 100%
• neutral: 0 0%
• negative: 0 0%

B of A Securities Tazeen Ahmad	$230	Buy Maintained	2 Sep 2025
JP Morgan Jessica Fye	$260	Overweight Maintained	19 Aug 2025
Citigroup David Lebowitz	$290	Buy Maintained	8 Aug 2025
RBC Capital Luca Issi	$230	Outperform Maintained	8 Aug 2025
Wedbush Yun Zhong	$220	Outperform Maintained	8 Aug 2025